Adjunctive ruxolitinib attenuates inflammation and enhances immunity in volunteers experimentally infected with Plasmodium falciparum.
Webster R, Oyong DA, Llewellyn S, Abd-Rahman AN, Potter AJ, Mukhiya R, Sahai N, Leelasena I, Ujvary E, Mathison S, Andrew DW, Bukali L, de Labastida Rivera F, Engel J, Soon MSF, Frame T, Hamelink J, Nalubega M, Dooley NL, Loughland JR, Nguyen T, Rosenberg-Hasson Y, Maysel-Auslender S, Sigal N, Foygel K, Gower J, Peters J, Woo R, Amante F, Wells TNC, Chalon S, Moehrle JJ, McCarthy JS, Birrell GW, Edstein MD, Leipold M, Obermoser G, Maecker H, Engwerda CR, Barber BE, Boyle MJ.
Webster R, et al. Among authors: mccarthy js.
Sci Transl Med. 2025 Nov 26;17(826):eaea2531. doi: 10.1126/scitranslmed.aea2531. Epub 2025 Nov 26.
Sci Transl Med. 2025.
PMID: 41296825
Clinical Trial.